Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.

@article{Kushner2016LackOS,
  title={Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.},
  author={Brian H. Kushner and Irina Ostrovnaya and Irene Y. Cheung and Deborah Kuk and Shakeel Modak and Kim Kramer and Stephen S. Roberts and Ellen M. Basu and Karima Yataghene and Nai-Kong V Cheung},
  journal={Oncotarget},
  year={2016},
  volume={7 4},
  pages={4155-66}
}
Since 2003, high-risk neuroblastoma (HR-NB) patients at our center received anti-GD2 antibody 3F8/GM-CSF + isotretinoin - but not myeloablative therapy with autologous stem-cell transplantation (ASCT). Post-ASCT patients referred from elsewhere also received 3F8/GM-CSF + isotretinoin. We therefore accrued a study population of two groups treated during the… CONTINUE READING